{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:53:57Z","timestamp":1789419237798,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04897-7","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:24:38Z","timestamp":1777569878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rational use of expensive medicines in the Netherlands: strategies to improve effectiveness and reduce burden on patients and society \u2013 a narrative review"],"prefix":"10.1186","volume":"24","author":[{"given":"Bart M.F.","family":"Penninx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atse","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9 L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"3","key":"4897_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S1470-2045(23)00592-2","volume":"25","author":"SN Koole","year":"2024","unstructured":"Koole SN, Huisman AH, Timmers L, et al. Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications. Lancet Oncol. 2024;25(3):126\u201335.","journal-title":"Lancet Oncol"},{"key":"4897_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.04.001","volume":"159","author":"TB Ribeiro","year":"2023","unstructured":"Ribeiro TB, Bennett CL, Colunga-Lozano LE, Araujo APV, Hozo I, Djulbegovic B. Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020). J Clin Epidemiol. 2023;159:151\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4897_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13023-018-0926-z","volume":"13","author":"C Pontes","year":"2018","unstructured":"Pontes C, Fontanet JM, Vives R, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. Orphanet J Rare Dis. 2018;13(1):206.","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"4897_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.19.02035","volume":"38","author":"AJ Templeton","year":"2020","unstructured":"Templeton AJ, Booth CM, Tannock IF. Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. J Clin Oncol. 2020;38(15):1651\u20134.","journal-title":"J Clin Oncol"},{"key":"4897_CR5","unstructured":"World Health Organisation (WHO). guideline on country pharmaceutical pricing policies 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240011878. Accessed 4-6-2025."},{"issue":"16","key":"4897_CR6","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.22.01799","volume":"41","author":"HM Khan","year":"2023","unstructured":"Khan HM, Ramsey S, Shankaran V. Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions. J Clin Oncol. 2023;41(16):3051\u20138.","journal-title":"J Clin Oncol"},{"key":"4897_CR7","unstructured":"World Health Organisation (WHO). The rational use of drugs: review of major issues Conference of experts on the rational use of drugs; Nairobi, Kenya 1985."},{"key":"4897_CR8","unstructured":"World Health Organisation (WHO). Policy Perspectives on Medicines, Promoting rational use of medicines: core components 2002. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/67438\/WHO_EDM_2002.3.pdf. Accessed 4-6-2025."},{"key":"4897_CR9","unstructured":"World Health Organisation (WHO). Promoting rational use of medicines. Available from: https:\/\/www.who.int\/activities\/promoting-rational-use-of-medicines. Accessed 20-11-2024."},{"issue":"1","key":"4897_CR10","doi-asserted-by":"publisher","first-page":"e002898","DOI":"10.1136\/rmdopen-2022-002898","volume":"9","author":"CJT van der Togt","year":"2023","unstructured":"van der Togt CJT, van den Bemt B, Aletaha D, et al. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 2023;9(1):e002898.","journal-title":"RMD Open"},{"issue":"3","key":"4897_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cpt.1853","volume":"108","author":"AV Serritella","year":"2020","unstructured":"Serritella AV, Strohbehn GW, Goldstein DA, Lichter AS, Ratain MJ. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020;108(3):487\u201393.","journal-title":"Clin Pharmacol Ther"},{"key":"4897_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40258-024-00937-6","volume":"23","author":"M Zietse","year":"2024","unstructured":"Zietse M, van der Zeeuw SL, Gebbink A-SK, et al. Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach. Appl Health Econ Health Policy. 2024;23:183\u201395.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"4897_CR13","first-page":"35","volume":"4","author":"R Ofori-Asenso","year":"2016","unstructured":"Ofori-Asenso R, Agyeman AA. Irrational Use of Medicines-A Summary of Key Concepts. Pharm (Basel). 2016;4(4):35.","journal-title":"Pharm (Basel)"},{"issue":"1","key":"4897_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.70239","volume":"208","author":"MR Seefat","year":"2026","unstructured":"Seefat MR, Cucchi DGJ, van Boven L, et al. Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma. Br J Haematol. 2026;208(1):337\u201342. https:\/\/doi.org\/10.1111\/bjh.70239.","journal-title":"Br J Haematol"},{"issue":"2","key":"4897_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamaneurol.2024.4164","volume":"82","author":"EME Coerver","year":"2025","unstructured":"Coerver EME, Fung WH, de Beukelaar J, et al. Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial. JAMA Neurol. 2025;82(2):123\u201331. https:\/\/doi.org\/10.1001\/jamaneurol.2024.4164.","journal-title":"JAMA Neurol"},{"issue":"5","key":"4897_CR16","first-page":"392","volume":"95","author":"AA Toorop","year":"2024","unstructured":"Toorop AA, van Lierop ZY, Gelissen LM, et al. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiatry. 2024;95(5):392\u2013400.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4897_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2023","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, et al. Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study. Kidney Int Rep. 2023;8(1):91\u2013102.","journal-title":"Kidney Int Rep"},{"key":"4897_CR18","doi-asserted-by":"publisher","first-page":"e079126","DOI":"10.1136\/bmj-2023-079126","volume":"386","author":"A Tibau","year":"2024","unstructured":"Tibau A, Hwang TJ, Avorn J, Kesselheim AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ. 2024;386:e079126.","journal-title":"BMJ"},{"issue":"4","key":"4897_CR19","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/cpt.3579","volume":"117","author":"SK Emond","year":"2025","unstructured":"Emond SK, Goettsch WG, Ollendorf DA. Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability. Clin Pharmacol Ther. 2025;117(4):938\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"4897_CR20","doi-asserted-by":"publisher","first-page":"101275","DOI":"10.1016\/j.lanepe.2025.101275","volume":"52","author":"CEM Hollak","year":"2025","unstructured":"Hollak CEM, Reparon-Schuijt CC, Verdeyen K, et al. New opportunities for accessing promising non-oncological orphan drugs. Lancet Reg Health Eur. 2025;52:101275.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"4897_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/stmcls\/sxae023","volume":"42","author":"A Soto-Gamez","year":"2024","unstructured":"Soto-Gamez A, Gunawan JP, Barazzuol L, Pringle S, Coppes RP. Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation. Stem Cells. 2024;42(6):499\u2013508.","journal-title":"Stem Cells"},{"key":"4897_CR22","unstructured":"Zorginstituut, Nederland. Veelbelovende zorg - Op de zorglocatie geproduceerde CD19 CAR T-celtherapie bij pati\u00ebnten met een recidief of refractair DLBCL. Available from: https:\/\/www.zorginstituutnederland.nl\/werkagenda\/kanker\/veelbelovende-zorg-cd19-car-t-celtherapie. Accessed 19-12-25."},{"key":"4897_CR23","unstructured":"Zorginstituut, Nederland. Veelbelovende zorg - Op de zorglocatie geproduceerde CAR T-celtherapie voor pati\u00ebnten met bepaalde auto-immuunziektes, die niet reageren op bestaande behandelingen. Available from: https:\/\/www.zorginstituutnederland.nl\/werkagenda\/kanker\/veelbelovende-zorg-op-de-zorglocatie-geproduceerde-car-t-celtherapie-voor-patienten-met-bepaalde-auto-immuunziektes-die-niet-reageren-op-bestaande-behandelingen. Accessed 29-12-25."},{"issue":"3","key":"4897_CR24","doi-asserted-by":"publisher","first-page":"e008372","DOI":"10.1136\/jitc-2023-008372","volume":"12","author":"RMT Ten Ham","year":"2024","unstructured":"Ten Ham RMT, Rohaan MW, Jedema I, et al. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial. J Immunother Cancer. 2024;12(3):e008372.","journal-title":"J Immunother Cancer"},{"key":"4897_CR25","doi-asserted-by":"publisher","first-page":"1264997","DOI":"10.3389\/fphar.2023.1264997","volume":"14","author":"N Bouwhuis","year":"2023","unstructured":"Bouwhuis N, Jacobs BAW, Kemper EM. Product development and quality of pharmacy compounded chenodeoxycholic acid capsules for Dutch cerebrotendinous xanthomatosis patients. Front Pharmacol. 2023;14:1264997.","journal-title":"Front Pharmacol"},{"key":"4897_CR26","unstructured":"Directorate-General for Health and Food Safety, European Commission. Proposal for a regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency: 2023. Available from: https:\/\/health.ec.europa.eu\/publications\/proposal-regulation-laying-down-union-procedures-authorisation-and-supervision-medicinal-products_en. Accessed 9-4-2025."},{"issue":"18","key":"4897_CR27","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04897-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T01:12:35Z","timestamp":1781745155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04897-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4897"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04897-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CEMH is a member of the Advisory Committee to the insured healthcare package (Dutch Healthcare Institute), chair of Medicines for Society and member of round table on orphan drugs (Dutch Healthcare Institute). NCAJvdK has received consulting fees from Samsung, Roche and Alexion and payments or honoraria from Sobi and Novartis. BMFP, SWT, LT, AH, DvdB, ZLEvK have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}